Verquvo (vericiguat) / Bayer, Merck (MSD), Chong Kun Dang - LARVOL DELTA

Association of Vericiguat with Improvement in Functional Abilities and Comprehensive Geriatric Assessment in Elderly Patients with Worsening Heart Failure. (PubMed, Pharmaceuticals (Basel)) - "These hypothesis-generating findings support the integration of CGA into future controlled studies of vericiguat in frail older patients with HFrEF. Given the observational design and lack of a control group, causal inference is not possible."

Journal • Cardiovascular • CNS Disorders • Congestive Heart Failure • Heart Failure

The effect of vericiguat on sudden cardiac death: insights from the VICTOR trial. (PubMed, Eur J Heart Fail) - No abstract available

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure

Improved endothelial function in heart failure outpatients with reduced ejection fraction after vericiguat therapy. (PubMed, J Cardiovasc Med (Hagerstown)) - "FMD variation at follow-up was inversely related to baseline FMD values (r = -0.52, P = 0.001). Three months of therapy with vericiguat in patients with HFrEF and worsening heart failure were associated with improved endothelial function assessed by FMD."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure

Vericiguat Alleviates Atrial Electrical and Structural Remodeling in Rats with Atrial Fibrillation. (PubMed, Anatol J Cardiol) - "Collectively, these findings suggest that vericiguat attenuates atrial remodeling and AF progression by modulating autophagy and suppressing fibrosis."

Journal • Preclinical • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Fibrosis • Heart Failure • Immunology • ATG7

ARETHA: The CardioMEMS Vericiguat Heart Failure Trial (clinicaltrials.gov) - P4 | N=17 | Completed | Sponsor: Finn Gustafsson | Active, not recruiting ➔ Completed

Trial completion • Cardiovascular • Congestive Heart Failure • Heart Failure

Efficacy of Vericiguat in Acute Heart Failure: A Target Trial Emulation Study. (PubMed, J Am Heart Assoc) - P | "In patients with acute HF, initiating vericiguat at discharge was observed to be associated with fewer HF rehospitalization events and improvements in New York Heart Association functional class over 180 days. These results suggest that vericiguat may have potential as a treatment option during the vulnerable postacute phase."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypotension

Efficacy and safety of vericiguat across the spectrum of heart failure: a systematic review and updated meta‑analysis of randomized controlled trials. (PubMed, Eur J Clin Pharmacol) - No abstract available

Journal • Retrospective data • Review • Cardiovascular • Congestive Heart Failure • Heart Failure

Effect of Vericiguat on cardiAc Remodeling in Patients With Heart faiLure and Reduced Ejection fractioN (HFrEF): A Prospective sTudy usIng NOvel Echocardiographic Imaging Techniques (VALENTINO) (clinicaltrials.gov) - P=N/A | N=40 | Completed | Sponsor: Chinese University of Hong Kong

New trial • Cardiovascular • Congestive Heart Failure • Heart Failure

ROLE OF LEFT ATRIAL STRAIN IN THE FOLLOW UP OF PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION AFTER ADDING VERICIGUAT TO OPTIMAL MEDICAL TREATMENT (ACC 2026) - "LAS did not significantly change after vericiguat but remained stable, suggesting a potential stabilizing effect. Correlations with NYHA, LVEF, NT-proBNP and LV GLS support the prognostic value of LAS in HFrEF."

Clinical • Atrial Fibrillation • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertrophic Cardiomyopathy • Inflammation

COMPARATIVE EFFECTIVENESS OF VERICIGUAT VS IVABRADINE IN HEART FAILURE WITH REDUCED EJECTION FRACTION: A PROPENSITY SCORE-MATCHED ANALYSIS (ACC 2026) - "In this large, real-world propensity-matched analysis of HFrEF patients, vericiguat demonstrated superior effectiveness compared to ivabradine, with significant reductions in both mortality and all-cause hospitalization. These findings suggest vericiguat may provide greater clinical benefit than ivabradine in HFrEF management, though further randomized controlled trials are warranted to confirm these observational findings and establish optimal treatment sequencing."

HEOR • Cardiovascular • Congestive Heart Failure • Heart Failure

COST-EFFECTIVENESS OF VERICIGUAT IN PATIENTS WITH HFREF WITHOUT RECENT HEART FAILURE WORSENING: INSIGHTS FROM THE VICTOR TRIAL (ACC 2026) - "In patients with HFrEF without recent worsening HF, vericiguat provides intermediate value by American College of Cardiology/American Heart Association standards."

Clinical • Cost effectiveness • HEOR • Cardiovascular • Congestive Heart Failure • Heart Failure

EARLY VERICIGUAT ADJUNCTIVE THERAPY IMPROVES LEFT VENTRICULAR REMODELING IN POST-AMI PATIENTS WITH REDUCED EJECTION FRACTION (ACC 2026) - "Early initiation of GDMT in post-AMI patients with reduced LVEF is associated with a significant reduction in HF incidence and slowing of disease progression. Adjunctive vericiguat therapy may provide additional benefits in attenuating adverse ventricular remodeling; however, these findings require confirmation in large-scale, randomized clinical trials to establish definitive therapeutic advantage."

Clinical • Cardiovascular • Congestive Heart Failure • Heart Failure • Myocardial Infarction

ADVERSE EVENTS OF VERICIGUAT IN CARDIAC FAILURE PATIENTS: A REAL-WORLD AND PHARMACOVIGILANCE DATABASE ANALYSIS (ACC 2026) - "In this real-world pharmacovigilance analysis, vericiguat use in patients with heart failure was most frequently associated with hypotension, worsening heart failure, and death, consistent with the clinical profile observed in the VICTORIA trial. We identify several AEs such as anemia, cardiac failure, and hypotension which were also reported in the VICTORIA trial, as well as other signals such as prescribing issues that may reflect real-world practice challenges not captured in trial settings. These findings underscore the importance of careful patient selection, monitoring for hypotension and anemia, and attention to treatment optimization when prescribing vericiguat in routine care."

Adverse events • Clinical • Real-world • Real-world evidence • Cardiovascular • Congestive Heart Failure • Dyspepsia • Heart Failure • Hematological Disorders • Hypotension • NPPB

VERICIGUAT IN HEART FAILURE: BENEFIT IN HFREF AND POTENTIAL HARM IN HFPEF BASED ON A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS (ACC 2026) - "Vericiguat significantly reduces cardiovascular mortality in HFrEF with safety profile comparable to placebo. However, in HFpEF, vericiguat shows a concerning trend towards harm."

Retrospective data • Cardiovascular • Congestive Heart Failure • Heart Failure

1058. SGLT2, Finerenone and Vericiguat in the Modern HFpEF Landscape (ACC 2026) - No abstract available

Cardiovascular

Heart Failure in the Era of Precision Medicine: Advances, Challenges, and Future Directions. (PubMed, Curr Cardiol Rev) - "Advances in HF therapeutics and precision medicine are reshaping patient care. Strategic implementation, equitable access, and continued innovation are critical to improving outcomes across diverse HF populations."

Journal • Amyloidosis • Cardiac Amyloidosis • Cardiovascular • Congestive Heart Failure • Heart Failure

Cyclic guanosine monophosphate-protein kinase G signaling attenuates aortic valve calcification through ULK1-mediated autophagy. (PubMed, Signal Transduct Target Ther) - "In vitro, PKGI silencing promoted osteogenic differentiation of human VICs, whereas pharmacological activation of cGMP-PKG signaling by vericiguat, BNP, or sildenafil attenuated calcium deposition, with vericiguat showing the strongest effect. Mechanistically, PKGI enhances autophagic flux by phosphorylating ULK1 at Ser556, preserving mitochondrial function, and reducing oxidative stress. Together, our work indicates that the cGMP-PKG pathway protects against aortic valve calcification by promoting ULK1-mediated autophagy, highlighting vericiguat as a potential therapy for CAVD."

Journal • Cardiovascular • ULK1

Early administration of renin-angiotensin system inhibitors improves survival and cardiac remodeling in heart failure with preserved ejection fraction. (PubMed, PLoS One) - "This study aimed to evaluate the preventive effects of RAS inhibitors captopril (Cap) and/or sacubitril/valsartan (Sac/Val) and sGC stimulator vericiguat (Ver) on HFpEF progression. Furthermore, RNA sequencing analysis showed that the expression of genes related to inflammatory response, hypertrophy, and extracellular matrix-receptor interaction increased in the HFpEF group and decreased in the Cap and Sac/Val groups. In conclusion, early administration of Cap or Sac/Val may reduce the risk of developing HFpEF by inhibiting the RAS pathway rather than the NO-sGC-cGMP pathway."

Journal • Cardiovascular • Congestive Heart Failure • Fibrosis • Heart Failure • Immunology • Inflammation

Differential cardiovascular benefits of SGLT2 inhibitors, sacubitril/valsartan, omecamtiv mecarbil, and vericiguat across heart failure phenotypes: a systematic review and meta-analysis. (PubMed, Front Pharmacol) - "Large-scale randomized trials are warranted to validate these findings. CRD42023455966."

Journal • Retrospective data • Review • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypotension

Vericiguat in Decompensated Cardiac Failure: Clinical Insights on Addition to Guidelines Derived Medical Therapy-VERCIG Trial (clinicaltrials.gov) - P1 | N=130 | Recruiting | Sponsor: Khawaja Danish Ali

New P1 trial • Cardiovascular • Congestive Heart Failure • Heart Failure

Vericiguat as a Novel Ferroptosis Inhibitor Alleviates Doxorubicin-Induced Cardiotoxicity. (PubMed, Basic Clin Pharmacol Toxicol) - "These findings indicate that vericiguat protects against doxorubicin-induced myocardial ferroptosis, positioning it as a promising therapeutic candidate for DIC and a novel ferroptosis inhibitor."

Journal • Cardiomyopathy • Cardiovascular • GPX4 • SLC7A11

Vericiguat Attenuates Post-Myocardial Infarction Inflammation Associated With Macrophage Polarization and Regulation of the Survivin/Caspase-6 Pathway. (PubMed, FASEB J) - "Furthermore, in vitro Survivin knockdown attenuated the ability of vericiguat to modulate macrophage polarization and inflammatory signaling. Collectively, these findings indicate that vericiguat-mediated cardioprotection is associated with immunomodulatory effects involving the Survivin/Caspase-6 pathway, providing new insights into the pleiotropic actions of sGC stimulation after myocardial infarction."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Inflammation • Myocardial Infarction • BIRC5 • CASP6

Role of vericiguat on renal function decline in patients with worsening heart failure (HEART FAILURE 2026) - No abstract available

Clinical • Cardiovascular • Congestive Heart Failure • Heart Failure

Real-word elegibiliy and tolerability of vericiguat in HFrEF: data from a multicenter registry (HEART FAILURE 2026) - No abstract available

Clinical • Cardiovascular • Congestive Heart Failure • Heart Failure

Vericiguat for HFrEF (HEART FAILURE 2026) - No abstract available

Cardiovascular • Congestive Heart Failure • Heart Failure